Received Mar 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 95BJ9 | IM / RA |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | DN273 | IM / RA |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y011500 | IM / LA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | Y013583 | SC / LA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y013583 | OT / LA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | OT |
No additional AE; patients may have received improperly stored PROQUAD since it "was stored in the refrigerator for months" instead of the freezer.; This spontaneous report was received from a Nurse and refers to a(n) 10-year-old female patient. The patient's medical history and previous drug reactions or allergies were not reported. Concomitant medications included Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil 9), Hepatitis b vaccine rHBsAg (yeast) (Engerix b) and Hepatitis a vaccine inact (Havrix). It was reported the on 01-OCT-2024, the dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) was moved from freezer to refrigerator until on 16-JAN-2025, when the patient was inadvertently administered with an improperly stored second dose (product storage error) of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) administered by subcutaneous route in Left Arm for prophylaxis (lot #Y013583, expiration date: 03-Feb-2026) reconstituted with sterile diluent. No additional AE.
Hep B (Engerix B); HEP A (Havrix); HPV (Gardasil 9)